Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (14185)	7/20/2000 3:05:57 AM
From: Bluegreen	Respond to of 17367

George, just to back up my statements about the best minds in the world haven't a clue of sepsis etiologies just theories. This fellow here says physicians not only don't have a clue but are ignorant about inflammatory responses of the body!!! Try telling Deitch that it is just a little old microcirculatory glitch!!! Enjoy>>>>>>>>>>>>>>>>Surg Clin North Am 1999 Dec;79(6):1471-88 Prevention of multiple organ failure. Deitch EA, Goodman ER Department of Surgery, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, USA. edeitch@umdnj.edu Physicians are still largely ignorant of the underlying biology of SIRS and multiple organ failure. Nonetheless, strategies to prevent multiple organ failure are possible. These include aggressive resuscitation of hemodynamically unstable patients, careful assessment to avoid missing clinically significant injuries, early operative treatment of all possible injuries with debridement of all nonviable tissue, early nutritional support, and the early diagnosis and prompt treatment of infectious complications. Treatment of patients with established multiple organ failure is still largely supportive and has made little impact on the patient mortality rate over the past 20 years. Future treatment strategies must focus on multimodality combination therapy aimed at specifically suppressing excessive activation of the inflammatory response while preserving immune competence and normal antimicrobial defenses. Only then are physicians likely to begin to see a reduction in the mortality rate of patients with this complex and challenging condition.<<<<<<<<<<<<<<

To: aknahow who wrote (14185)	7/20/2000 9:04:24 AM
From: Robert K.	Read Replies (1) \| Respond to of 17367

No George, I totally disagree. The protein c find is magnitudes more important. Reasons are> Merck >threw bpi in for good measure. Lilly> made a deliberate attempt to link the 2 products specifically in a patent. Also Zovant is halted for a presumed good result. Now you have lilly saying"we think we have something better" via their patent. Think george, a deliberate attempt, not a throw-in. We all know myco has synergy. Thats obvious. Lilly has been playing with bpi imo.